Tolerance induction for EGFR TKI hypersensitivity in lung cancer: Case report and review
This report highlights the successful use of oral desensitization to manage delayed-type hypersensitivity to afatinib, enabling continuation of treatment for epidermal growth factor receptor-mutated non-small cell lung cancer. In the absence of standardized protocols, it offers valuable insights for managing similar clinical challenges.
Authors
- Sachiko Kaburagi
- Takeya Adachi (ORCID: https://orcid.org/0000-0002-5289-5980)
- Katsunori Masaki (ORCID: https://orcid.org/0000-0003-0909-9409)
- Junko Kagyo
- Koichi Fukunaga (ORCID: https://orcid.org/0000-0001-7460-1990)
- Mizuha Hashiguchi (ORCID: https://orcid.org/0000-0002-4698-1655)
- Masato Asaoka
- Utako Okata-Karigane
- Umi Tahara
- Tamaki Ito
- Suzuyuki Yoneda
- Chiaki Takahashi
Institutions
- Keio University (JP)
- Keio University Hospital (JP)
- keiyu Hospital (JP)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1016/j.jacig.2026.100706
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Japanese Society of Allergology
- Secom Science and Technology Foundation